Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.35 |
| ▸ | OTC | P00480 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 5/20 | 0.34 |
| ▸ | NPY1R | P25929 | 4/20 | 0.34 |
| ▸ | NPY2R | P49146 | 4/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7250716 | 1.00 | ALOX15 (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL7250717 | 1.00 | ALOX15 (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL287680 | 0.95 | ALOX15 (0.40) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL27999717 | 0.95 | ALOX15 (0.40) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL287554 | 0.89 | S1PR2 (0.34) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL21690029 | 0.89 | S1PR2 (0.34) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL15984911 | 0.89 | S1PR2 (0.34) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Arginine SCHEMBL136113 | 0.87 | OTC (0.48) | ALOX15MEN1CYP1A2KMT2AOTC | |
| SCHEMBL288471 | 0.85 | S1PR2 (0.37) | MEN1KMT2AITGB3ITGA2BS1PR2 | |
| SCHEMBL23988668 | 0.84 | ALOX15 (0.37) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314016-A1 | CYCLIC CELL PENETRATING PEPTIDES | Entrada Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2022240758-A1 | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION | ENTRADA THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| WO-2022213118-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| US-20030055053-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives | PFIZER INC. | 2003-03-20 | — | — | US | claimed |
| US-20020016297-A1 | 4-oxo-2- ureido-1,4,5,6,-tetrahydro-pyrimidine derivatives | LINDE ROBERT G (US) | 2002-02-07 | — | — | US | claimed |
| EP-1113008-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | claimed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-1113008-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | ALOX15 1296/4885MEN1 332/4885CYP1A2 882/4885 |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | ALOX15 4783/4885MEN1 350/4885CYP1A2 4798/4885 |
| US-20030055053-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives | UMPS, UPP1, UGP2 | ALOX15 1455/4885MEN1 2006/4885CYP1A2 170/4885 |
| US-20020016297-A1 | 4-oxo-2- ureido-1,4,5,6,-tetrahydro-pyrimidine derivatives | UMPS, UPP1, NUDT1 | ALOX15 1796/4885MEN1 1899/4885CYP1A2 219/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | ALOX15 4319/4885MEN1 559/4885CYP1A2 3255/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | ALOX15 355/4885MEN1 1674/4885CYP1A2 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.